RESUMO
Resumen Diferentes linajes de las células hepáticas participan en la regeneración del hígado y los hepatocitos guiescentes pueden responder ante un daño hepático leve con división celular moderada, mientras gue las células troncales y progenitoras responderán para una amplia restitución del parénquima hepático severamente dañado. Ocho linajes madurativos se sitúan dentro del hígado con diferente grado de madurez. Cuatro de ocho subpoblaciones gue presentan marcadores para células troncales o progenitoras se ubican en nichos intrahepáticos como los canales de Hering y la vena porta, estructuras en las gue pueden continuar su diferenciación si se recibe algún estímulo. Recientemente se describió un nuevo nicho entrahepático con una composición celular heterogénea ubicado entre los grandes duetos biliares y en el páncreas. Las células gue se encuentran en estos compartimentos expresan marcadores tempranos de células troncales y se consideran como precursores de las células troncales hepáticas.
Abstract Different cellular lineages participate in liver regeneration. Quiescent hepatocytes may respond to a mild liver injury with moderate cell division. Meanwhile, stem and progenitor cells are responsible for the large restitution of a severe damaged organ. Eight matu rational lineages are in the liver, each one with a different maturity grade. Four subpopulations out of eight express stem or progenitor cell markers are found within intrahepatic niches such as the canals of Hering and the portal vein. Each structure is able to continue its differentiation if a stimuli is received. Recently, a new extra-hepatic stem niche with a heterogeneous cellular composition was found between the large biliary ducts and the pancreas. Stem or progenitor cells contained in these compartments express early stem markers and are considered as a precursor of hepatic stem cells.
RESUMO
We studied the pharmacokinetics of amikacin in a patient with acute oliguric renal failure during continuous veno-venous hemofiltration (CVVH). The volume of distribution, terminal disposition rate constant and elimination half-life for amikacin were 27.9 L, 0.023.h-1 and 29.7 h, respectively. Total body clearance for amikacin was 10.54 ml/min and CVVH clearance was 10.11 ml/min. Sieving coefficient for amikacin was 0.93 +/- 0.16. Our data show that during CVVH at a filtration rate of 10 ml/min, the clearance of amikacin is similar to that reported in patients with renal failure who are not being treated with CVVH.